Zealand Pharma AS
(OTCPK:ZLDPF)
$
42.89
(0%)
Market Cap: 3.02 Bil
Enterprise Value: 847.50 Mil
PE Ratio: 3.17
PB Ratio: 1.38
GF Score: 62/100 Zealand Pharma A/S at Goldman Sachs Healthcare Conference Transcript
Jun 09, 2026 / 05:20PM GMT
Release Date Price:
$42.03
(+7.91%)
Rajan Sharma
Goldman Sachs Group Inc - Analyst
Good afternoon, everyone. Thanks for joining us. My name is Rajan Sharma, European pharma and biotech analyst here at Goldman Sachs. Very pleased to have Zealand Pharma with us and Adam Steensberg, CEO, Adam, thank you. Thanks for joining.
I know that you've been on the road with ADA. So thanks for adding on this to the trip.
Adam Steensberg;S;President
Zealand Pharma A;Chief Executive Officer, Member of the Executive Management
/- -
Pleased to be here.
Questions & Answers
Rajan Sharma;Adam Steensberg<
Goldman Sachs Group Inc - Analyst
Lots to get through. And obviously, we're coming off the back of ADA. So maybe that's a good place to start. There are a few updates there, both with Survodutide and Petrelintide. Could you maybe just start with Survodutide because that was kind of the more the newer update that we got over the weekend?
And just provide your thoughts on the data.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot